TipRanks
Idexx Laboratories (CH:IX1)
:IX1

Idexx Laboratories (IX1) Price & Analysis

0 Followers

IX1 Stock Chart & Stats

Currently, no data available
Please return soon. This page is being updated.

Bulls Say, Bears Say

Bulls Say
Recurring Diagnostics GrowthStrong recurring diagnostic growth demonstrates durable demand beyond clinic visit volumes and supports predictable revenue from consumables and services. The premium to U.S. visit trends also indicates effective pricing, workflow integration, and customer retention.
High And Expanding ProfitabilityHigh margins and continued expansion indicate strong pricing, scale benefits, and cost control across the diagnostic platform. Sustained profitability gives IDEXX resources to fund innovation and commercial investment while preserving meaningful earnings power.
Strong Cash GenerationRobust free cash flow and healthy conversion show that reported earnings are translating into usable cash. This supports ongoing research, product launches, debt management, and shareholder returns without requiring heavy external financing.
Bears Say
U.S. Visit PressurePersistent declines in U.S. clinical and wellness visits can constrain test volumes and slow growth in visit-linked services. Continued consumer pressure and slower pet additions may delay volume recovery, even if IDEXX retains share and gains pricing.
Growth NormalizationA more mature growth profile reduces the contribution from pure top-line acceleration and places greater importance on execution, pricing, and innovation. Slower revenue expansion can also limit operating leverage and make future earnings growth less forgiving.
Lean Equity Base SensitivityAlthough leverage is described as manageable, a relatively lean equity base can amplify reported returns and increase sensitivity if profitability weakens. Lower equity cushioning may make earnings volatility more pronounced during a period of slower growth.

Idexx Laboratories News

IX1 FAQ

What was Idexx Laboratories’s price range in the past 12 months?
Currently, no data Available
What is Idexx Laboratories’s market cap?
Idexx Laboratories’s market cap is CHF35.52B.
    When is Idexx Laboratories’s upcoming earnings report date?
    Idexx Laboratories’s upcoming earnings report date is Nov 02, 2026 which is in 15 days.
      How were Idexx Laboratories’s earnings last quarter?
      Idexx Laboratories released its earnings results on Aug 04, 2026. The company reported CHF3.518 earnings per share for the quarter, beating the consensus estimate of CHF3.249 by CHF0.269.
        Is Idexx Laboratories overvalued?
        According to Wall Street analysts Idexx Laboratories’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Idexx Laboratories pay dividends?
          Idexx Laboratories does not currently pay dividends.
          What is Idexx Laboratories’s EPS estimate?
          Idexx Laboratories’s EPS estimate is 3.07.
            How many shares outstanding does Idexx Laboratories have?
            Idexx Laboratories has 78,781,110 shares outstanding.
              What happened to Idexx Laboratories’s price movement after its last earnings report?
              Idexx Laboratories reported an EPS of CHF3.518 in its last earnings report, beating expectations of CHF3.249. Following the earnings report the stock price went same N/A.
                Which hedge fund is a major shareholder of Idexx Laboratories?
                Currently, no hedge funds are holding shares in CH:IX1
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  Idexx Laboratories

                  IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.

                  Idexx Laboratories (IX1) Earnings & Revenues

                  IX1 Company Deck

                  IX1 Earnings Call

                  Q2 2026
                  0:00 / 0:00
                  Earnings Call Sentiment|Positive
                  The call conveyed a strongly constructive operational and financial picture: solid organic revenue growth (~9% Q2), recurring CAG Diagnostics strength, robust margin and EPS expansion, strong free cash flow and aggressive capital returns, plus clear product and innovation momentum (inVue Dx, Cancer Dx, Catalyst SDMA). Offsetting items include continued pressure on U.S. clinic and wellness visits, a Q2 instrument revenue lap effect, foreign-exchange headwinds, and planned incremental investments that will temper near-term margin gains. Overall, the positive drivers — durable recurring revenue expansion, margin gains, cash generation, and multiple innovation milestones — materially outweigh the cited headwinds.View all CH:IX1 earnings summaries

                  IX1 Revenue Breakdown

                  91.86%91.86%4.67%3.06%0.41%
                  91.86% CAG
                  4.67% Water
                  3.06% LPD
                  0.41% Other
                  tipranks

                  IX1 Stock 12 Month Forecast

                  Average Price Target

                  ―
                  eyJuYXZpZ2F0b3IiOnsiZGlzYWJsZWQiOnRydWV9LCJleHBvcnRpbmciOnsiZW5hYmxlZCI6ZmFsc2V9LCJ0aXRsZSI6eyJ0ZXh0IjpudWxsfSwiY2hhcnQiOnsiaGVpZ2h0IjoyMDAsInN0eWxlIjp7ImZvbnRGYW1pbHkiOiJSb2JvdG8gRmxleCwgLWFwcGxlLXN5c3RlbSwgQmxpbmtNYWNTeXN0ZW1Gb250LCBTZWdvZSBVSSwgUm9ib3RvLCBIZWx2ZXRpY2EsIEFyaWFsLCBzYW5zLXNlcmlmLCBBcHBsZSBDb2xvciBFbW9qaSwgU2Vnb2UgVUkgRW1vamksIFNlZ29lIFVJIFN5bWJvbCIsImZvbnRXZWlnaHQiOiI0MDAiLCJjb2xvciI6IiM1ZDVkNWUifX0sInlBeGlzIjp7ImxhYmVscyI6eyJzdHlsZSI6eyJjb2xvciI6ImluaGVyaXQifX0sInZpc2libGUiOmZhbHNlfSwicGxvdE9wdGlvbnMiOnsic2VyaWVzIjp7InN0YXRlcyI6eyJpbmFjdGl2ZSI6eyJvcGFjaXR5IjoxfX19fSwieEF4aXMiOnsibGFiZWxzIjp7InN0eWxlIjp7ImNvbG9yIjoiaW5oZXJpdCJ9fSwidmlzaWJsZSI6ZmFsc2V9LCJsZWdlbmQiOnsic3ltYm9sUmFkaXVzIjowLCJzeW1ib2xQYWRkaW5nIjo0LCJzeW1ib2xIZWlnaHQiOjE0LCJib3JkZXJXaWR0aCI6MCwic3ltYm9sV2lkdGgiOjE0LCJhbGlnbiI6ImxlZnQiLCJ2ZXJ0aWNhbEFsaWduIjoiYm90dG9tIiwiZW5hYmxlZCI6ZmFsc2V9LCJ0b29sdGlwIjp7ImJhY2tncm91bmRDb2xvciI6IndoaXRlIn0sImNyZWRpdHMiOnsiZW5hYmxlZCI6ZmFsc2V9LCJhY2Nlc3NpYmlsaXR5Ijp7ImRlc2NyaXB0aW9uIjoiIn0sInNlcmllcyI6W3sidHlwZSI6ImFyZWEiLCJkYXRhIjpbXX1dfQ==
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Agilent
                  ―
                  ―
                  Danaher
                  ―
                  ―
                  Illumina
                  ―
                  ―
                  Thermo Fisher
                  ―
                  ―
                  Waters
                  ―
                  ―
                  Popular Stocks